Liao Chun-Ta, Chang Joseph Tung-Chieh, Wang Hung-Ming, Ng Shu-Hang, Hsueh Chuen, Lee Li-Yu, Lin Chih-Hung, Chen I-How, Huang Shiang-Fu, Cheng Ann-Joy, Yen Tzu-Chen
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Cancer. 2007 Aug 1;110(3):564-71. doi: 10.1002/cncr.22814.
According to the American Joint Commission on Cancer (AJCC, 5(th) edition) classification system, pT4 N0 oral cavity squamous cell carcinoma (OSCC) qualifies for stage IVA status, with its implied poor prognosis. However, preliminary observations suggested that patients with pT4 N0 OSCC might have better survival than other stage IVA categories. The authors sought to identify accurate prognosticators in patients with stage III/IVA OSCC.
The authors retrospectively reviewed 513 consecutive patients with stage III/IVA OSCC who were undergoing radical surgery. Survival was plotted by Kaplan-Meier analysis.
One hundred seventy-eight patients were in stage III, and 335 were in stage IVA. The 335 stage IVA patients were divided into pT4 N0 (n = 105) and pT4 N1/TAny N2 (NO pT4 N0 M0, n = 230). By univariate analysis, 5-year neck control rates (P < .0001), distant metastases (P < .0001), disease-free survival rates (P < .0001), and overall survival rates (P < .0001) were significantly different in pT4 N0 compared with NO pT4 N0 patients. No significant difference in survival between pT4 N0 stage IVA and pstage III could be shown. Multivariate analysis for overall survival demonstrated that the following factors were independently associated with pT4 N0: tumor depth >or=35 mm, vessel invasion, lymph invasion, and perineural invasion. In contrast, tumor depth >or=25 mm, treatment with surgery alone, poor differentiation, extracapsular spread, and pathological nodal metastases (>or=8 lymph nodes) were independent predictors of overall survival in NO pT4 N0.
In patients with stage IVA OSCC (AJCC, 1997), the survival rates for pT4 N0 are better than those for NO pT4 N0 and similar to those of patients with pstage III.
根据美国癌症联合委员会(AJCC,第5版)分类系统,pT4 N0口腔鳞状细胞癌(OSCC)属于IVA期,其预后较差。然而,初步观察表明,pT4 N0 OSCC患者的生存率可能优于其他IVA期患者。作者试图确定III/IVA期OSCC患者的准确预后指标。
作者回顾性分析了513例接受根治性手术的连续性III/IVA期OSCC患者。采用Kaplan-Meier分析绘制生存曲线。
178例患者为III期,335例为IVA期。335例IVA期患者分为pT4 N0(n = 105)和pT4 N1/TAny N2(无pT4 N0 M0,n = 230)。单因素分析显示,与无pT4 N0患者相比,pT4 N0患者的5年颈部控制率(P <.0001)、远处转移(P <.0001)、无病生存率(P <.0001)和总生存率(P <.0001)有显著差异。pT4 N0 IVA期与III期之间的生存率无显著差异。总生存的多因素分析表明,以下因素与pT4 N0独立相关:肿瘤深度≥35 mm、血管侵犯、淋巴侵犯和神经周围侵犯。相比之下,肿瘤深度≥25 mm、单纯手术治疗、低分化、包膜外扩散和病理淋巴结转移(≥8个淋巴结)是无pT4 N0患者总生存的独立预测因素。
在IVA期OSCC(AJCC,1997)患者中,pT4 N0的生存率优于无pT4 N0患者,与III期患者相似。